OVERVIEW
	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
	José Baselga and Carlos L. Arteaga
	JCO Apr 10 2005: 2445–2459. First published on Mar 7 2005; 10.1200/JCO.2005.11.890. [Abstract] [Full Text] [PDF]

ORIGINAL REPORTS
Predictive Biomarkers/Translational Research
	Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers
	Syed K. Mohsin, Heidi L. Weiss, M. Carolina Gutierrez, Gary C. Chamness, Rachel Schiff, Michael P. DiGiovanna, Chun-Xia Wang, Susan G. Hilsenbeck, C. Kent Osborne, D. Craig Allred, Richard Elledge, and Jenny C. Chang
	JCO Apr 10 2005: 2460–2468. First published on Feb 14 2005; 10.1200/JCO.2005.00.661. [Abstract] [Full Text] [PDF]
	Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase
	M. Carolina Gutierrez, Simone Detre, Stephen Johnston, Syed K. Mohsin, Jiang Shou, D. Craig Allred, Rachel Schiff, C. Kent Osborne, and Mitch Dowsett
	JCO Apr 10 2005: 2469–2476. First published on Mar 7 2005; 10.1200/JCO.2005.01.172. [Abstract] [Full Text] [PDF]
	Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT Trialists
	Mitch Dowsett, Steve R. Ebbs, J. Michael Dixon, Anthony Skene, Clive Griffith, Irene Boeddinghaus, Janine Salter, Simone Detre, Margaret Hills, Susan Ashley, Stephen Francis, Geraldine Walsh, and Ian E. Smith
	JCO Apr 10 2005: 2477–2492. First published on Mar 14 2005; 10.1200/JCO.2005.07.559. [Abstract] [Full Text] [PDF]
	Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
	Sae-Won Han, Tae-You Kim, Pil Gyu Hwang, Soohyun Jeong, Jeongmi Kim, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Dong-Wan Kim, Doo Hyun Chung, Seock-Ah Im, Young Tae Kim, Jong Seok Lee, Dae Seog Heo, Yung-Jue Bang, and Noe Kyeong Kim
	JCO Apr 10 2005: 2493–2501. First published on Feb 14 2005; 10.1200/JCO.2005.01.388. [Abstract] [Full Text] [PDF]
	Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
	Neil L. Spector, Wenle Xia, Howard Burris, III, Herbert Hurwitz, E. Claire Dees, Afshin Dowlati, Bert O'Neil, Beth Overmoyer, Paul K. Marcom, Kimberly L. Blackwell, Deborah A. Smith, Kevin M. Koch, Andrew Stead, Steven Mangum, Matthew J. Ellis, Leihua Liu, Albert K. Man, Troy M. Bremer, Jennifer Harris, and Sarah Bacus
	JCO Apr 10 2005: 2502–2512. First published on Jan 31 2005; 10.1200/JCO.2005.12.157. [Abstract] [Full Text] [PDF]
	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
	Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, and Yasushi Yatabe
	JCO Apr 10 2005: 2513–2520. First published on Feb 28 2005; 10.1200/JCO.2005.00.992. [Abstract] [Full Text] [PDF]

Clinical Trials
	Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors
	Josep Tabernero, Fredy Rojo, Irene Marimón, Maurizio Voi, Joan Albanell, Marta Guix, Federico Vázquez, Joan Carulla, Michael Cooper, Jordi Andreu, Anne Van Vreckem, Joaquim Bellmunt, Veeraswamy Manne, James A. Manning, Carmen Garrido, Enriqueta Felip, Josep Maria del Campo, Mónica García, Sonia Valverde, and José Baselga
	JCO Apr 10 2005: 2521–2533. First published on Feb 14 2005; 10.1200/JCO.2005.00.398. [Abstract] [Full Text] [PDF]
	Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
	David B. Agus, Michael S. Gordon, Charles Taylor, Ronald B. Natale, Beth Karlan, David S. Mendelson, Michael F. Press, David E. Allison, Mark X. Sliwkowski, Gracie Lieberman, Stephen M. Kelsey, and Gwen Fyfe
	JCO Apr 10 2005: 2534–2543. First published on Feb 7 2005; 10.1200/JCO.2005.03.184. [Abstract] [Full Text] [PDF]
	Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer
	Roy S. Herbst, David H. Johnson, Eric Mininberg, David P. Carbone, Ted Henderson, Edward S. Kim, George Blumenschein, Jr, Jack J. Lee, Diane D. Liu, Mylene T. Truong, Waun K. Hong, Hai Tran, Anne Tsao, Dong Xie, David A. Ramies, Robert Mass, Somasekar Seshagiri, David A. Eberhard, Sean K. Kelley, and Alan Sandler
	JCO Apr 10 2005: 2544–2555. First published on Mar 7 2005; 10.1200/JCO.2005.02.477. [Abstract] [Full Text] [PDF]

REVIEW ARTICLE
	Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions
	William Pao and Vincent A. Miller
	JCO Apr 10 2005: 2556–2568. First published on Mar 14 2005; 10.1200/JCO.2005.07.799. [Abstract] [Full Text] [PDF]

ART OF ONCOLOGY

Inter-Religious Perspectives on Hope and Limits in Cancer Treatment

Alan B. Astrow, Ingrid Mattson, Rabbi James Ponet, and Michelle White

JCO Apr 10 2005: 2569–2573. [Full Text] [PDF]

GLOSSARY

Glossary

JCO Apr 10 2005: 2577–2582. [PDF]

SPECIAL DEPARTMENTS

Correspondence

Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy

Manish A. Shah, David Ilson, and David P. Kelsen

JCO Apr 10 2005: 2574–2576. First published on Mar 28 2005; 10.1200/JCO.2005.81.908. [Full Text] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.